[144] Hims & Hers Health, Inc. SEC Filing

Rhea-AI Filing Summary

Hims & Hers Health, Inc. (HIMS) filed a Form 144 reporting that insider Michael Y. Chi plans to sell up to 13,750 Class A shares through Fidelity Brokerage on or after 07/23/2025. At the stated aggregate market value of $770,000, the sale equals roughly 0.006 % of the company’s 215,453,899 shares outstanding, implying minimal dilution or governance impact.

The shares stem from option exercises dated 02/24/2022, 08/10/2022 and 03/01/2023, all paid in cash on 07/23/2025. Chi has already sold 27,602 shares in the prior three months, generating $1.62 million in gross proceeds at prices recorded on 06/06, 06/10 and 06/17 2025.

Although the volume is modest versus float, continued dispositions may be interpreted by some investors as an insider sentiment signal. No new operational or financial metrics are included in the filing.

Positive

• Sale volume is only 0.006 % of shares outstanding, implying negligible dilution or control impact.
• Transparent Rule 144 disclosure allows investors to monitor insider activity in real time.

Negative

• Continued insider selling (41,352 shares including planned sale) within four months can be perceived as a bearish sentiment signal.
• No accompanying business updates to offset potential negative perception of insider dispositions.

Insights

Securities Analyst

TL;DR – Small, routine insider sale; negligible balance-sheet impact, watch sentiment.

The proposed sale of 13,750 shares (~$0.77 M) is immaterial to HIMS’s 215 M share base. Coupled with 27.6 k shares sold since June, the pattern looks like ongoing liquidity from option exercises rather than strategic divestment. No fundamentals change; therefore, the filing is neutral in valuation terms, but repeated selling could weigh on short-term sentiment for momentum traders.

Corporate Governance Expert

TL;DR – Governance neutral; disclosure complies, but insider selling trend bears monitoring.

Chi’s sale is properly disclosed under Rule 144 and represents <0.01 % of shares, posing no control risk. However, incremental insider dispositions—three in the last quarter plus this notice—may attract scrutiny from investors tracking insider confidence metrics. Absent larger aggregated sales or undisclosed adverse information (affirmatively denied in the form), governance concern is low.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	13750	770000.00	215453899	07/23/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	07/23/2025	Option Granted - 02/24/2022	Issuer			12600	07/23/2025	Cash
Class A	07/23/2025	Option Granted - 08/10/2022	Issuer			900	07/23/2025	Cash
Class A	07/23/2025	Option Granted - 03/01/2023	Issuer			250	07/23/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael Y. Chi 2269 Chestnut Street #523 San Francisco CA 94123	Class A	06/06/2025	5100	285600.00
Michael Y. Chi 2269 Chestnut Street #523 San Francisco CA 94123	Class A	06/10/2025	5400	307800.00
Michael Y. Chi 2269 Chestnut Street #523 San Francisco CA 94123	Class A	06/17/2025	17102	1021844.50

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many HIMS shares does Michael Y. Chi plan to sell under this Form 144?

Chi intends to sell 13,750 Class A shares with an estimated value of $770,000.

What percentage of Hims & Hers Health’s outstanding shares does the proposed sale represent?

Roughly 0.006 % of the 215,453,899 shares outstanding.

Have there been recent insider sales by the same individual?

Yes. Chi sold 27,602 shares between 06/06/2025 and 06/17/2025 for $1.62 million in gross proceeds.

When is the earliest date the shares may be sold?

The approximate sale date disclosed is 07/23/2025 via the NYSE.

Are these shares newly issued or option-exercised?

They arise from option exercises granted in 2022 and 2023, paid for in cash on 07/23/2025.

Does the filing include any financial performance data for HIMS?

No. Form 144 only addresses proposed insider share sales and contains no operational or earnings metrics.